MX2020002560A - Tratamiento con mazindol de la dependencia a la heroina y el trastorno de uso de sustancias. - Google Patents

Tratamiento con mazindol de la dependencia a la heroina y el trastorno de uso de sustancias.

Info

Publication number
MX2020002560A
MX2020002560A MX2020002560A MX2020002560A MX2020002560A MX 2020002560 A MX2020002560 A MX 2020002560A MX 2020002560 A MX2020002560 A MX 2020002560A MX 2020002560 A MX2020002560 A MX 2020002560A MX 2020002560 A MX2020002560 A MX 2020002560A
Authority
MX
Mexico
Prior art keywords
mazindol
substance
treatment
substance use
use disorder
Prior art date
Application number
MX2020002560A
Other languages
English (en)
Inventor
Alexander C Zwyer
Original Assignee
Nls 1 Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nls 1 Pharma Ag filed Critical Nls 1 Pharma Ag
Publication of MX2020002560A publication Critical patent/MX2020002560A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Addiction (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se refiere a mazindol para usarse en el tratamiento de la dependencia y trastorno por el uso de una sustancia, en donde la sustancia es un opioide; a una composición que comprende mazindol y opcionalmente un vehículo o excipiente y/o diluyente farmacéuticamente aceptable, para usarse en el tratamiento del trastorno por el abuso de una sustancia, en donde la sustancia es un opioide; y a un método de tratamiento de un trastorno por el abuso de una sustancia, que comprende administrarle mazindol o una composición que comprende mazindol a un sujeto, en donde la sustancia es un opioide. Preferiblemente el opioide es heroína.
MX2020002560A 2017-09-07 2018-09-06 Tratamiento con mazindol de la dependencia a la heroina y el trastorno de uso de sustancias. MX2020002560A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762555469P 2017-09-07 2017-09-07
PCT/IB2018/001138 WO2019058172A1 (en) 2017-09-07 2018-09-06 MAZINDOLE TREATMENT FOR HEROID DEPENDENCE AND DISORDER RELATED TO THE USE OF PSYCHOACTIVE SUBSTANCES

Publications (1)

Publication Number Publication Date
MX2020002560A true MX2020002560A (es) 2020-07-13

Family

ID=64316589

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020002560A MX2020002560A (es) 2017-09-07 2018-09-06 Tratamiento con mazindol de la dependencia a la heroina y el trastorno de uso de sustancias.

Country Status (9)

Country Link
US (1) US11596622B2 (es)
EP (1) EP3678661A1 (es)
JP (1) JP2020533295A (es)
KR (1) KR20200085730A (es)
CN (1) CN111343979A (es)
BR (1) BR112020004506A2 (es)
CA (1) CA3074054A1 (es)
MX (1) MX2020002560A (es)
WO (1) WO2019058172A1 (es)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5217987A (en) * 1989-10-30 1993-06-08 Berger Stephen P Dopamine uptake inhibitors in reducing substance abuse and/or craving
US6323242B1 (en) 1998-12-02 2001-11-27 Peter Sterling Mueller Treatment of disorders secondary to organic impairments
FR2899476B1 (fr) 2006-04-11 2008-07-04 Assist Publ Hopitaux De Paris Association du mazindol dans le traitement du deficit de l'attention/hyperactivite
CA2793777C (en) * 2010-03-31 2019-04-16 Supernus Pharmaceuticals, Inc. Formulations of mazindol
US9687445B2 (en) 2012-04-12 2017-06-27 Lts Lohmann Therapie-Systeme Ag Oral film containing opiate enteric-release beads
EP3928770A1 (en) 2016-03-09 2021-12-29 NLS Pharmaceutics AG A mazindol ir/sr multilayer tablet and its use for the treatment of attention deficit/hyperactivity disorder (adhd)

Also Published As

Publication number Publication date
US11596622B2 (en) 2023-03-07
KR20200085730A (ko) 2020-07-15
US20210161865A1 (en) 2021-06-03
CA3074054A1 (en) 2019-03-28
JP2020533295A (ja) 2020-11-19
WO2019058172A1 (en) 2019-03-28
BR112020004506A2 (pt) 2020-09-15
EP3678661A1 (en) 2020-07-15
CN111343979A (zh) 2020-06-26

Similar Documents

Publication Publication Date Title
PH12018500642A1 (en) Anti-garp antibody
MX2019001125A (es) Inhibidores de cinasa macrociclica.
MX2014010590A (es) Terapia de combinacion para trastornos proliferativos.
SG10201810888XA (en) Compositions and methods comprising bupropion or related compounds and dextromethorphan
WO2015054619A3 (en) Use of a pcsk9 inhibitor to treat hyperlipidemia
SG10201811128RA (en) Ezh2 inhibitors for treating lymphoma
MX2017017138A (es) Conjugados homogeneos especificos de sitio con inhibidores de ksp.
MX2017006437A (es) Compuestos espiroisoquinolin-1,4'-piperidinicos con actividad multimodal contra el dolor.
MA39765A (fr) Formulation pharmaceutique d'un inhibiteur de la kinase pan-raf, ses procédés de préparation, et procédés d'utilisation
MX2016008397A (es) Composicion para usarse en el tratamiento de tos persistente.
PH12016502233A1 (en) (s)-pirlindole or its pharmaceutically acceptable salts for use in medicine
MX2023000187A (es) Dosificacion de vibegron para el tratamiento de vejiga sobreactiva.
CA3010788A1 (en) Methods of administering vasopressors
MX2015000485A (es) Tratamiento de esclerosis multiple con una combinacion de laquinimod y fampridina.
PH12018500814A1 (en) Oxadiazaspiro compounds for the treatment of drug abuse and addiction
MX2015013155A (es) Formulaciones farmaceuticas de la familia de la tetrandrina y metodo.
PH12018550008A1 (en) Selected amide of y-hydroxybutyric acid and uses thereof in the treatment of alcohol misuse
MX2022014792A (es) Cocristales, composiciones farmaceuticas de los mismos y metodos de tratamiento que los implican.
MY186840A (en) Method for treating psoriasis patient which received anti-tnf-alpha antibody therapy
CA3011003A1 (en) Bacterial ghosts for the treatment of cancer
PH12016502236A1 (en) (r)-pirlindole and its pharmaceutically acceptable salts for use in medicine
MX2016006894A (es) Terapia de combinacion que comprende un inhibidor de jak, cdk y pim.
MY197664A (en) Immunity enhancing agent for cancer by allergin-1 antagonist
MX2020002560A (es) Tratamiento con mazindol de la dependencia a la heroina y el trastorno de uso de sustancias.
MX2016001177A (es) Tratamiento de esclerosis multiple con la combinacion de laquinimod y flupirtina.